Navigation Links
Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Date:9/4/2007

CORONA, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received its first U.S. Food and Drug Administration (FDA) product approval at its Goa, India facility. During the next several months the company plans to seek FDA approval to manufacture additional solid dosage products at the facility. By early 2008, the Goa facility is expected to be producing over 1 billion tablets and capsules annually for the U.S. market.

"This approval represents a key milestone for Watson, demonstrating our rapid progress toward building an offshore infrastructure," said Allen Chao, Ph.D., Watson's Executive Chairman. "In the coming months we anticipate making additional FDA submissions to transfer certain products to this facility to achieve efficiencies in scale and cost. This will enhance our ability to provide quality, low cost generic pharmaceutical products to the U.S. marketplace."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, difficulties or delays in transferring product manufacturing to the Goa facility; difficulties or delays in obtaining U.S. Food and Drug Administration or other regulatory approvals to manufacture products at the Goa, India site for the U.S. market; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Pravastatin Launched by Watson Pharmaceuticals
3. Watson Amazed by Radcliffes Steamy Shots
4. Infant receives first bloodless liver transplant
5. Fifth US Patient Receives Artificial Heart
6. Northfield Labs Receives FDA Comments
7. British MPs Say Prostate Cancer Receives Low Priority in the NHS
8. Abbott Receives CE Mark Certification
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes ... and around the nation. What do they have in common? All have been affected ... compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance ... to families and business owners in the greater Dallas metropolitan area, is announcing ... Fallen Officer Foundation. , Established in 2009 by active police professionals in the ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 ... Winner in the Folio: Marketing Awards competition. Live From won in the Use ... pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most innovative ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- KEY FINDINGS Patient warming and ... loss of blood during surgeries, lowering the risks ... after surgeries, and decreasing risks of SSIs. The ... warming system, surface warming systems, and intravascular warming ... at hospitals thus, lowering the healthcare costs by ...
(Date:12/7/2016)... 7, 2016 Research and Markets has announced ... User - Global Forecast to 2021" report to their offering. ... , , ... by 2021, growing at a CAGR of 7.3% during the forecast period ... prevalence of cancer and rapidly increasing geriatric population across the globe are ...
(Date:12/7/2016)... Dec. 7, 2016 DelveInsight,s, "Janus ... provides in depth insights on the pipeline ... Janus Kinase 3 (JAK3) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Medicine Technology: